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Purpose of the study
We assessed endocrine system involvement in a multifac-
torial pathogenesis hypothesis of NAFLD in HIV-infected
patients.
Methods
Cross-sectional observational study including all consecu-
tive HIV-infected patients seen at a metabolic clinic who
were screened for diabetes, thyroid dysfunction, male
hypogonadism, female menopause, hypopituitarism.
NAFLD was defined by liver-spleen attenuation values of
≤1.1 on computed tomography.
Summary of results
225 patients were included. (Table 1.)
We included endocrine variables (but not sex hormones)
and known independent predicting variables (sex, waist
circumference, ALT/AST, NRTI cumulative exposure) in a
backward stepwise multivariate logistic regression analy-
sis. Independent variables associated with NAFLD were
NRTI cumulative exposure (OR = 1.11 per year; CI 1.01–
1.20), ALT/AST (OR = 3.97; CI 1.78–8.87), waist circum-
ference (OR = 1.06; CI 1.03–1.11). When including sex
hormones in different gender groups insulin increased
predictive value in female only (OR = 1.18; CI 1.03, 1.34).
Conclusion
Homeostasis of glucose appears the only endocrine sys-
tem associated with NAFLD.
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Male, n (%) 71 (85.54) 92 (64.79) < .001*
Age, yrs 48.43 ± 8.16 48.04 ± 8.84 .74**
CDC C, n (%) 41 (28.87) 21 (25.30) .14*
ALT/AST 1.46 ± 0.52 1.12 ± 0.38 < .001 **
Waist, cm
Total 90.26 ± 9.24 83.87 ± 9.27 < .001 **
Men 90.27 ± 8.41 85.13 ± 8.42 < .001 **
Women 90.18 ± 14.00 81.57 ± 10.35 .022 **
NRTI Cumulative Exp, months 124.16 ± 44.86 109.85 ± 49.16 .033 **
NNRTI Cumulative Exp, months 41.94 ± 30.43 35.54 ± 30.13 .15 **
PI Cumulative Exp, months 61.34 ± 36.87 60 ± 39.73 .81 **
Hormones
TSH 1.93 ± 1.21 2.20 ± 1.57 .19 **
T4 11.01 ± 1.48 10.71 ± 1.38 .14 **
Insulin, median (IQR) 17.1 (11.65; 22.8) 10.2 (7.4; 16.5) < .001§
LH, median (IQR) n = 60 4.6 (2.8; 9.5) 6.2 (4; 19.2) .38§
FSH, (IQR) n = 60 4 (2.2; 8.9) 6.3 (4; 20.1) .21§
17-beta-estradiol, (IQR) n = 60 81 (27; 104) 89 (38; 145) .42§
Total testosterone, (IQR) n = 152 483 (372; 583) 433 (343; 531) .11§
Free testosterone, (IQR) n = 152 13.2 (9.6; 16.8) 13 (8.8; 16.3) .64§
GH, (IQR) .11 (.06; .35) .28 (.08; 1.04) .003§
IGF1 132.32 ± 57.65 141.75 ± 61.33 .26 **
IGFBP3, (IQR) 3210 (2240; 4280) 3382 (2050; 4297) .90§
Endocrine syndromes
Hypothyroidism TSH ≥3.5, n (%) 7 (8.43) 18 (12.68) .11*
Diabetes Fasting glucose ≥126 mg/dL 20 (24.10) 17 (11.97) .018*
MenopauseLH and FSH > 20 ng/mL and 17 beta-estradiol < 40 pg/mL n = 62 2 (16.67) 7 (14) .81*
Hypogonadism testosterone < 200 ng/dL n = 163 3 (3.26) 1 (1.41) .29*
Hypopituitarism IGF-1 < 73 pg/mL and IGFBP3 < 1157 pg/mL 13 (15.66) 25 (17.61) .70*
* chi-squared test; ** T-test; §Mann-Whitney test.Page 2 of 2
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